Skip to main content
OpenTrials
Completed

NCT Number: NCT01777373

Conducting Airways in Lung Fibrosis (VACFI)

The purpose of this study is to determine whether extension of the conducting airways into the distal lung, or bronchiolization, occurs early in the course of Idiopathic Pulmonary Fibrosis, a disease wherein normal lung structures are destroyed and replaced by non-functional scar tissue.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpital Bichat

Paris, 75018, France

About this study

Diffuse Interstitial Pneumonias are a heterogeneous group of chronic respiratory diseases. Idiopathic Pulmonary Fibrosis, one of such diseases, is characterized by lesions of the conducting airways including extension of bronchioles towards the distal lung, or bronchiolization of the distal lung. Such lesions are traditionally referred to as "traction bronchiectasis" although no evidence supports a cause-and-effect relationship between alveolar fibrosis and airway lesions. Another feature of IPF is chronic, invalidating dry cough. Our hypothesis is that IPF is characterized by early increases in the volume of conducting airways, that such changes correlate with cough, and that airway changes are in direct relation with airway fibrosis. The primary aim of this study is to demonstrate increased anatomical dead space (VD), a surrogate for conducting airway volume, in patients with moderate (or early) IPF, in comparison with subjects without any respiratory disease ("non-DIP controls"). The secondary aims are : To show that VD is increased in patients with IPF in comparison with patients with other DIPs ("DIP controls"), to show that in patients with IPF increased VD does not correlate with indices of alveolar fibrosis, and to show associations between increased VD and cough and other respiratory symptoms in patients with IPF.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

IPF :

Inclusion criteria

  • Age 18-85 years
  • IPF diagnosed according to ATS/ERS/JRS/ALAT criteria
  • Patient gave informed consent

NON INCLUSION CRITERIA

  • Presence of respiratory comorbidities : Asthma, COPD, bronchiectasis, emphysema, tuberculosis sequelae, prior lung surgery
  • Obstructive ventilatory disorder
  • Counterindication to pulmonary function testing
  • Women : Pregnancy or milking
  • Lack of health insurance

Controls :

Inclusion criteria

  • Volunteers aged 18-85 years, free of any respiratory disease
  • Volunteer gave informed consent

Secondary EXCLUSION CRITERIA Abnormal PFT : Total lung capacity or FEV1/VC ratio < Lower Limit of Normal

Non-IPF ILD :

Inclusion criteria

  • Age 18-85 years
  • Radiological interstitial pneumonia, on 2 tests performed >3 months apart
  • PINS histology OR sarcoidosis histology OR clinical diagnosis of drug-induced lung disease OR diagnosis of auto-immune disease
  • Patient gave informed consent

NON INCLUSION CRITERIA

  • Presence of respiratory comorbidities : Asthma, COPD, bronchiectasis, emphysema, tuberculosis sequelae, prior lung surgery
  • Obstructive ventilatory disorder
  • Counterindication to pulmonary function testing
  • Women : Pregnancy or milking
  • Lack of health insurance

Uncharacterized ILD :

Inclusion criteria

  • Age 18-85 years
  • Radiological interstitial pneumonia, on 2 tests performed >3 months apart
  • Patient gave informed consent

NON INCLUSION CRITERIA

  • Presence of respiratory comorbidities : Asthma, COPD, bronchiectasis, emphysema, tuberculosis sequelae, prior lung surgery
  • Obstructive ventilatory disorder
  • Counterindication to pulmonary function testing
  • Women : Pregnancy or milking
  • Lack of health insurance

Secondary EXCLUSION CRITERIA Final diagnosis other than either IPF or non-IPF interstitial pneumonia.

Treatment and study plan

Primary outcomes

  1. Fowler dead space

    Time frame: 1 day

    Conducting airway volume is determined by Fowler's method from volumetric capnography data

Secondary outcomes

  1. Bohr anatomic dead space

    Time frame: 1 day

    Bohr anatomic dead space is determined from capnography and spirometry data.

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Conducting Airways in Lung Fibrosis

Acronym: VACFI

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
Jan 28, 2013
Registry last updated
Apr 10, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.